Stay updated on Nivolumab in AML Remission at High Risk Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in AML Remission at High Risk Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The record now displays details for the nivolumab phase 2 study in acute myeloid leukemia, including its protocol, eligibility criteria, outcomes, and posted results information.
    Difference
    48%
    Check dated 2026-11-08T13:28:20.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now identifies the site revision as v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-11-01T14:34:48.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A banner was added announcing changes to NIH websites and noting that both “Super Intelligence” and “Artificial Intelligence” may appear during the transition.
    Difference
    1%
    Check dated 2026-10-25T13:36:52.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T14:15:08.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T14:48:18.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error page, replacing the previous study-record content with a site-wide access-denied screen; additions include the 403 message and related header information.
    Difference
    18%
    Check dated 2026-09-20T19:44:54.000Z thumbnail image

Stay in the know with updates to Nivolumab in AML Remission at High Risk Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.